Artificial intelligence (AI) holds tremendous potential to accelerate advancements across health and medicine, but it also comes with risks if not applied carefully, as evidenced by dueling results from recent cancer treatment studies.
On the one hand, UK-based biotech startup Etcembly just announced that it was able to use generative AI to design a novel immunotherapy that targets hard-to-treat cancers. This represents the first time an immunotherapy candidate was developed using AI, and Etcembly—which is a member of Nvidia’s Inception program—was able to create it in just 11 months, or twice as fast as conventional methods.
Etcembly’s new therapeutic, called ETC-101, is a bispecific T cell engager, which means it targets a protein found in many cancers and not healthy tissue. It also demonstrates picomolar affinity, and is thus up to a million times more potent than natural T cell receptors.
The company says it also has a robust pipeline of other immunotherapies for cancer and autoimmune diseases designed by its AI engine, called EMLy.
“Etcembly was born from our desire to bring together two concepts that are ahead of the scientific mainstream—TCRs and generative AI—to design the next generation of immunotherapies,” said CEO Mich
Go to Source to See Full Article
Author: Jose Antonio Lanz
Tip BTC Newswire with Cryptocurrency